ABSTRACT
Today, with only 4% of the world’s population, the U.S. is bearing a disproportionate share of COVID-19 infections. Seeking to understand this puzzle, we investigate how mitigation strategies and compliance can work together (or in opposition) to reduce (or increase) the spread of COVID-19 infection. Drilling down to the state level, we create specific state indices suitable for the U.S. to measure the degree of strictness of public mitigation measures. In this, we build on the Oxford Stringency Index. A modified time-varying SEIRD model, incorporating this Stringency Index as well as a Compliance Indicator to reduce the transmission, is then estimated with daily data for a sample of 6 U.S. states. These are New York, New Hampshire, New Mexico, Colorado, Texas, and Arizona. We provide a simple visual policy tool to evaluate the various combinations of mitigation policies and compliance that can reduce the basic reproduction number to less than one; this is the acknowledged threshold in the epidemiological literature to control the pandemic. States successful in combating the pandemic were able to achieve a suitable combination. Understanding of this relationship by the public and policy makers is key to controlling the pandemic. This tool has the potential to be used in a real-time, dynamic fashion for flexible policy options.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This paper is not supported by any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This paper is based on public data. There is no human subjects or any clinical trials involved.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data used in this paper are public data. All the data resources are listed in the reference list in this manuscript.